Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CTX110 |
Synonyms | |
Therapy Description |
CTX110 consists of a preparation of allogeneic T-lymphocytes engineered with CRISPR/Cas9 to express a chimeric antigen receptor (CAR) targeting CD19 and to simultaneously remove the endogenous T cell receptor, which potentially reduces GVHD and induces killing of tumor cells overexpressing CD19 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CTX110 | CTX-110|CTX 110|anti-CD19 CAR CRISPR-edited CTX110 | CD19 Immune Cell Therapy 62 | CTX110 consists of a preparation of allogeneic T-lymphocytes engineered with CRISPR/Cas9 to express a chimeric antigen receptor (CAR) targeting CD19 and to simultaneously remove the endogenous T cell receptor, which potentially reduces GVHD and induces killing of tumor cells overexpressing CD19 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04035434 | Phase Ib/II | CTX110 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies | Active, not recruiting | USA | FRA | ESP | DEU | CAN | AUS | 0 |